Group 1 - The company has received approval from the National Medical Products Administration for the clinical trial of "Lung Heat Cough and Asthma Granules" [1][2] - The drug is an improved version of the already marketed "Pediatric Lung Heat Cough and Asthma Granules," now targeting adults and including additional indications for influenza [2] - The drug is classified as a Type 2.3 modified traditional Chinese medicine, suitable for treating symptoms related to heat toxin attacking the lungs [2] Group 2 - After obtaining the clinical trial approval, the drug must undergo clinical trials and receive further evaluation from the National Medical Products Administration before it can be produced and marketed [3]

Core Viewpoint - The company ST HuLuWa (605199) has received approval from the National Medical Products Administration for clinical trials of its new product, a modified version of the existing "Pediatric Lung Heat Cough and Asthma Granules," now targeting adult influenza patients [1] Group 1: Product Development - The new product is an improvement on the already marketed "Pediatric Lung Heat Cough and Asthma Granules" [1] - The modified formulation expands its indications to include "heat toxin attacking the lung syndrome" associated with influenza in adults [1] - The product is designed to clear heat and detoxify, relieve cough, and reduce phlegm and wheezing, applicable for conditions like cold, bronchitis, wheezing bronchitis, and bronchopneumonia [1]